XML 29 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets
12 Months Ended
Jun. 30, 2020
Intangible Assets
Note 5. Intangible Assets
Intangible assets consisted of the following, in thousands: 
 
   
June 30,
 
   
2020
   
2019
 
S*Bio Patents—Gross
  $273   $500 
Less: accumulated amortization
   (273   (239
  
 
 
   
 
 
 
Intangible assets, net
  $   $261 
  
 
 
   
 
 
 
Amortization expense of intangible assets for the years ended June 30, 2020, 2019 and 2018 was $34,000, $35,000 and $35,000, respectively.
As a result of Helsinn discontinuing the Phase 3 study of pracinostat in AML, we assessed the estimated future cash flows associated with the patents acquired from S*Bio and recorded an impairment charge of
$0.2
million to write off the remaining book value of the intangible assets.